Weekly NIH Funding Opportunities and Notices for September 06, 2019

Policy Notices

- Notice of Special Interest to Encourage Eligible NIH BRAIN Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
  (NOT-MH-19-038)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke

General Notices

- Notice of Pre-Application Webinar for RFA-AT-20-001, Preclinical Screening for Natural Product Drug Interactions (R21) and RFA-AT-20-002, Center of Excellence for Natural Product Drug interaction Research (U54)
  (NOT-AT-19-034)
  National Center for Complementary and Integrative Health

- Pre-Application Webinar for RFA-CA-19-033 "Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)"
  (NOT-CA-19-068)
  National Cancer Institute

- The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Mid-Atlantic Regional Workshop on Sexual and Gender Minority (SGM)-Related Health Research
  (NOT-OD-19-142)
  Office of the Director, NIH

- Request for Information (RFI): Soliciting Additional Input to the All of Us Research Program 2019 Tribal Consultation
  (NOT-PM-19-004)
  National Institutes of Health

Notice of Changes to Funding Opportunities
• Notice of Increased Budget Limits and NINDS Participation in PAS-19-316 "Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)"
  (NOT-AG-19-040)
  National Institute on Aging
  National Institute of Neurological Disorders and Stroke

• Notice of Change to Information relevant to Specific Institutes/Centers in PAR-19-274, "Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)"
  (NOT-AR-19-040)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

• Notice of Change to Information relevant to Specific Institutes/Centers in PAR-19-275, "Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)"
  (NOT-AR-19-041)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

• Notice of Correction to Award Budget for RFA HD-20-006 "US Children with Perinatal HIV who were Born Internationally (R01 Clinical Trial Optional)"
  (NOT-HD-19-025)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• NHLBI Announces Participation in PA-18-932 "Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)"
  (NOT-HL-19-719)
  National Heart, Lung, and Blood Institute

• Notice to Extend, PA-18-400 "Research on Autism Spectrum Disorders (R21-Clinical Trial Optional)"
  (NOT-MH-19-045)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke

• Notice to Extend, PA-18-401 "Research on Autism Spectrum Disorders (R01-Clinical Trial Optional)"
  (NOT-MH-19-046)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences
  National Institute of Neurological Disorders and Stroke

• Notice to Extend, PA-18-399 "Research on Autism Spectrum Disorders (R03-Clinical Trial Optional)"
  (NOT-MH-19-047)
  National Institute of Mental Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Deafness and Other Communication Disorders
  National Institute of Environmental Health Sciences

• Notice to Extend, PAR-18-479, "Detecting and Preventing Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R01 Clinical Trial Required)"
Notice to Extend, PAR-18-228, "Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System (R34 Clinical Trial Required)"
(NOT-MH-19-050)
National Institute of Mental Health

Notices of Intent to Publish

- Notice of Intent to Publish a Funding Opportunity Announcement for the Pediatric HIV AIDS Cohort Study Program Project Grant Applications (P01 Clinical Trial Not Allowed)
  (NOT-HD-19-024)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

Notices of Special Interest

- Notice of Special Interest: High-Priority Research Topics for PA-19-053 and PA-19-056
  (NOT-AG-19-037)
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases

- Notice of Special Interest (NOSI) of NIDCD and NEI in Supporting Research on Usher Syndrome
  (NOT-DC-19-007)
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute

- Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases
  (NOT-DK-19-015)
  National Institute of Diabetes and Digestive and Kidney Diseases

- Notice of Special Interest: Research to Improve Pre-Pregnancy Care and Enhance Healthy Birth Intervals
  (NOT-HD-19-019)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Notice of Special Interest: Mechanisms Underlying the Contribution of Sleep Disturbances to Pain
  (NOT-HD-19-020)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

Funding Opportunities

- Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)
  (PAR-19-357)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Dates listed below.
Planning Grant for Global Infectious Disease Research Training Program (D71 No Clinical Trials Allowed)
(PAR-19-362)
John E. Fogarty International Center
Application Receipt Date(s): November 12, 2019, October 28, 2020, October 28, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
(PAR-19-363)
National Cancer Institute
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 5, 2019

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)
(PAR-19-364)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Dates listed below.

Revision Applications for Mechanisms of Drug Resistance (R01 Clinical Trials Not Allowed)
(RFA-CA-19-049)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021. No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Revision Applications for Mechanisms of Drug Resistance (U01 Clinical Trials Not Allowed)
(RFA-CA-19-050)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021. No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Revision Applications for Mechanisms of Drug Resistance (U54 Clinical Trials Not Allowed)
(RFA-CA-19-051)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021. All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the
revision applications for mechanisms of drug resistance (p01 clinical trials not allowed)
(rfa-ca-19-052)
national cancer institute
application receipt date(s): october 24, 2019; june 24, 2020; october 22, 2020, june 23, 2021. all applicants are due by 5:00 pm local time of applicant organization. all types of non-aids applications allowed for this funding opportunity announcement are due on the listed date(s). applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. no late applications will be accepted for this funding opportunity announcement.

revision applications for mechanisms of drug resistance (p50 clinical trials not allowed)
(rfa-ca-19-053)
national cancer institute
application receipt date(s): october 24, 2019; june 24, 2020; october 22, 2020, june 23, 2021. all applicants are due by 5:00 pm local time of applicant organization. all types of non-aids applications allowed for this funding opportunity announcement are due on the listed date(s). applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. no late applications will be accepted for this funding opportunity announcement.

the national drug abuse treatment clinical trials network (ug1 clinical trial required)
(rfa-da-20-024)
national institute on drug abuse
application receipt date(s): november 15, 2019. all applications are due by 5:00 pm local time of applicant organization. all types of non-aids applications allowed for this funding opportunity announcement are due on the listed date(s). no late applications will be accepted for this funding opportunity announcement. applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

prevention of lower urinary tract symptoms (plus) research consortium clinical research centers (u01 clinical trial optional)
(rfa-dk-19-015)
national institute of diabetes and digestive and kidney diseases
application receipt date(s): november 7, 2019

prevention of lower urinary tract symptoms (plus) research consortium scientific and data coordinating center (u24 clinical trial optional)
(rfa-dk-19-016)
national institute of diabetes and digestive and kidney diseases
application receipt date(s): november 7, 2019

using archived data and specimen collections to advance maternal and pediatric hiv/aids research (r21 clinical trial not allowed)
(rfa-hd-20-020)
eunicef kennedy shrive national institute of child health and human development
application receipt date(s): november 1, 2019

trans-agency blood-brain interface program (r61/r33 - clinical trials not allowed)
(rfa-hl-20-021)
Mechanistic Basis of TDP-43-dependent Pathobiology in Common Dementias (R01 Clinical Trial not Allowed) (RFA-NS-20-005)
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Application Receipt Date(s): November 15, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Peripheral Pathology in the Lewy Body Dementias (R01 Clinical Trial Not Allowed) (RFA-NS-20-014)
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Application Receipt Date(s): The due date for this FOA is December 3, 2019 No late applications will be accepted for this Funding Opportunity Announcement